Southern Capital Advisors LLC Sells 747 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by MarketBeat News on Aug 4th, 2022

Johnson & Johnson logo Southern Capital Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 24.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,360 shares of the company’s stock after selling 747 shares during the period. Southern Capital Advisors LLC’s holdings in Johnson & Johnson were worth $418,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Family CFO Inc bought a new position in shares of Johnson & Johnson in the 4th quarter worth $26,000. Steward Financial Group LLC bought a new position in Johnson & Johnson during the 4th quarter valued at $34,000. Joseph P. Lucia & Associates LLC bought a new position in Johnson & Johnson during the 1st quarter valued at $38,000. Advocacy Wealth Management Services LLC lifted its stake in Johnson & Johnson by 41.4% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after acquiring an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC bought a new position in Johnson & Johnson during the 4th quarter valued at $49,000. 68.78% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 1.0 %

Shares of JNJ opened at $174.59 on Thursday. The business has a 50-day moving average of $175.57 and a 200 day moving average of $174.49. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The firm has a market cap of $459.42 billion, a P/E ratio of 25.41, a price-to-earnings-growth ratio of 3.31 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. During the same quarter last year, the firm posted $2.48 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, research analysts forecast that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating on the stock. Credit Suisse Group raised their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Morgan Stanley raised their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. UBS Group decreased their target price on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Wells Fargo & Company raised their target price on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.